Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

Here's What to Expect From Gilead Sciences’ Next Earnings Report

Gilead Sciences, Inc. (GILD), based in Foster City, California, is a leading biopharmaceutical company focused on developing and commercializing groundbreaking therapies for diseases like HIV, liver conditions, cancer, and inflammation. Its market cap currently stands at $129 billion. 

Gilead is poised to release its fiscal Q1 earnings results after the market closes on Thursday, Apr. 24. Ahead of the event, analysts expect GILD to report a profit of $1.73 per share, up 231.1% from the loss of $1.32 per share in the year-ago quarter. The company surpassed Wall Street’s bottom-line estimates in each of the past four quarters, which is impressive.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.